Black Licorice Compound Shows Potential for IBD

A compound best known for giving black licorice its distinct flavor now sits at the center of a promising new path in inflammatory bowel disease research.

Researchers report that they built a stem cell-based model of the human intestine designed to mimic key features of IBD, a chronic condition marked by painful inflammation and damage in the digestive tract. That model gave scientists a more human-like testing ground for new therapies, potentially speeding up a field that often struggles to translate early lab results into effective treatments.

The finding points to two advances at once: a more realistic way to search for IBD drugs and a natural compound that appears to blunt intestinal injury.

After screening thousands of compounds, the team identified glycyrrhizin — a natural substance found in black licorice — as a leading anti-inflammatory candidate. Reports indicate the compound reduced intestinal damage and cell death tied to IBD in both lab-grown tissue and mice, a combination that gives the result more weight than a single test system alone.

The work does not mean black licorice itself has become a treatment, and the findings remain an early-stage research signal rather than a clinical answer. Still, the study suggests scientists may have found both a useful drug candidate and a stronger tool for discovering others. In a disease area where patients often cycle through imperfect options, that matters.

What comes next will determine whether this promise holds up: researchers will need to confirm safety, dosage, and effectiveness in further studies before any human use comes into view. If the intestine model keeps producing credible leads, it could reshape how IBD therapies move from discovery to development — and give patients a faster route to better treatments.